The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The current return on assets of Icosavax suggests not a very effective usage of assets in December.
The company had not issued any dividends in recent years.
Use Technical Analysis to project Icosavax expected Price
Icosavax technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, delisted stock market cycles, or different charting patterns.
A focus of Icosavax technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Icosavax trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions.
More Info...Deferred Revenue Breakdown
Icosavax Deferred Revenue yearly trend continues to be fairly stable with very little volatility. Deferred Revenue will likely drop to about 2.1
M in 2021. Deferred Revenue usually refers to a component of Total Liabilities representing the carrying amount of consideration received or receivable on potential earnings that were not recognized as revenue; including sales; license fees; and royalties; but excluding interest income. Icosavax Deferred Revenue is fairly stable at the moment as compared to the past year. Icosavax reported Deferred Revenue of 2.15 Million in 2020
| 2010 | 2.38 Million |
| 2020 | 2.15 Million |
| 2021 | 2.13 Million |
Is Icosavax showing appearance of lower volatility?
Current standard deviation is at 7.42. Icosavax is displaying above-average volatility over the selected time horizon. Investors should scrutinize Icosavax independently to ensure intended market timing strategies are aligned with expectations about Icosavax volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Icosavax's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Icosavax's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Icosavax Implied Volatility
Icosavax's implied volatility exposes the market's sentiment of Icosavax stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Icosavax's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Icosavax stock will not fluctuate a lot when Icosavax's options are near their expiration.
Our Final Takeaway
While many other companies in the biotechnology industry are either recovering or due for a correction, Icosavax may not be performing as strong as the other in terms of long-term growth potentials. To conclude, as of the 13th of December 2021, we believe Icosavax is currently
undervalued. It follows the market closely and projects
quite high probability of financial unrest in the next two years. Our actual 90 days buy vs. sell advice on the company is
Cautious Hold.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Icosavax. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
